Gavin Giovannoni.

Dawson, M.D. For the DEFINE Research Investigators: Placebo-Controlled Phase 3 Research of Oral BG-12 for Relapsing Multiple Sclerosis Oral BG-12 has been investigated for the treatment of multiple sclerosis. Irritation and oxidative stress are central pathologic elements in multiple sclerosis.1,2 Immune cell activation and infiltration into the central nervous system are thought to result in widespread cellular damage, potentially due to the dysregulated production and release of reactive oxygen and nitrogen species, such as hydrogen peroxynitrite and peroxide, and proinflammatory stimuli.3 This mix of toxic factors results in demyelination and neurodegeneration ultimately, leading to disease activity and progression of disability.1,4 BG-12 could also are likely involved in modulating immune-cell responses by shifting dendritic-cell differentiation,5 suppressing proinflammatory-cytokine production, or inhibiting proinflammatory pathways directly.Fellows spend period on both the Chronic Pain Services and Acute Pain Service, with ample period allotted for didactic periods and multidisciplinary meetings at BIDMC and additional Harvard teaching hospitals. Effective completion leads to certification eligibility by the American Table of Anesthesiology. Related StoriesBRCA gene mutations and ovarian malignancy: an interview with Dr Matulonis, Harvard Medical SchoolAddressing standard of living needs in prostate malignancy: an interview with Professor Louis DenisAdvances in thoracic medical procedures: an interview with Dan Wildman, VP Global Franchise Technique & Creativity – EthiconAAPM extends its congratulations to Christine Peeters-Asdourian, MD, Program Director, the Beth Israel Deaconess INFIRMARY Pain Medicine Fellowship Plan and its own staff and faculty.